NCT03977272View on ClinicalTrials.gov

Combination of Anti-PD-1 Antibody and Chemotherapy in Metastatic Pancreatic Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

110

Participants

Timeline

Start Date

March 27, 2019

Primary Completion Date

July 1, 2022

Study Completion Date

July 1, 2022

Conditions
Pancreatic Cancer
Interventions
DRUG

Combination drug

Accompanying with modified-FOLFIRINOX, Anti-PD-1 antibody was applied biweekly

DRUG

Chemotherapy

modified-FOLFIRINOX

Trial Locations (1)

310003

the First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou

All Listed Sponsors
lead

Zhejiang University

OTHER

NCT03977272 - Combination of Anti-PD-1 Antibody and Chemotherapy in Metastatic Pancreatic Cancer | Biotech Hunter | Biotech Hunter